Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis

m, 52-week, parallel-group study, whereby patients will be given five subcutaneous injections at 0, 4, 8, 12 and 24 weeks. The analyses will be performed at the end of the 52-week study to assess the safety and efficacy of Tovaxin. The primary efficacy variable is the cumulative number of gadolinium-enhancing lesions on T1-weighted MRI scans summed over the Week 28, 36, 44, and 52 MRIs. The secondary efficacy variables are the cumulative number of new gadolinium-enhancing lesions at Weeks 28-52, the change in T2-weighted lesion volume, and the annualized relapse rate. As of May 17, 2007, Opexa announced the completion of patient enrollment in a 150-patient Phase IIb safety and efficacy study (TERMS). All patients who complete the trial will be eligible to participate in an optional one-year extension study, in which they will receive Tovaxin under an open-label protocol. The open-label study is being planned under a different protocol that will be submitted to the FDA.

The TERMS study is being conducted at 36 U.S. sites to evaluate the safety and effectiveness of Tovaxin. The TERMS study is registered on the U.S. National Institutes of Health-sponsored website, www.clinicaltrials.gov, where pharmaceutical companies are required to register trials for medicines that will treat serious or life-threatening diseases or conditions. For more information, visit the TERMS website at www.tovaxin.com.

About T-cell Vaccination

For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in multiple sclerosis patients resulted in the in vivo induction of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... announces that a new market research report is ... Butadiene Market In Americas To 2020 - Recovery ... In The Region ... To 2020 - Recovery In End Use Markets ...
... Reportlinker.com announces that a new market research report is ... Marker Diagnostic Testing Markets ... Publications report is to describe the specific market segment ... cardiac marker testing. This study examines clinical measurement devices ...
Cached Medicine Technology:Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 2Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 3Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 4Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 5Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 6Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 7Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 8Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region 9Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 2Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 3Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 4Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 5Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 6Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 7Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 8
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2
... 10 (HealthDay News) -- A positive attitude and a ... to an expert. Women should start preparing when ... begins in the 40s, but can start as early ... of obstetrics/gynecology at Gottlieb Memorial Hospital, Loyola University Health ...
... end of this year, colonoscopy screening will have prevented ... was introduced in Germany. This is the result obtained ... in Heidelberg and his co-authors in their interim assessment ... the German cancer screening program. The authors present their ...
... drinking glasses, and other children,s products constitute an ongoing ... in these products and other changes in policy and ... ACS, Environmental Science & Technology , a semi-monthly ... Massey note that in June the United States government ...
... 9 (HealthDay News) -- Long-term use of androgen deprivation therapy ... broken bones, according to a new study. These findings ... use this therapy in older men with localized disease, the ... men, aged 66 and older, who survived at least five ...
... Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience ... that Docosahexaenoic acid (DHA), a component of fish oil, ... and promote recovery in an experimental model of acute ischemic ... hours. These findings not only target a new stroke treatment ...
... New research shows a gene-based test for lung ... likely to benefit from CT screening for lung cancer, ... the American Association of Cancer Research,s Ninth Annual Conference ... that included 1,216 lung cancer cases and 1,200 controls ...
Cached Medicine News:Health News:Positive Attitude, Planning May Help Women Through Menopause 2Health News:Fracture Risk Seen With Hormone Therapy for Prostate Cancer 2Health News:Louisiana State University Health Sciences Center research shows fish oil component given up to 5 hours after stroke limits brain damage 2Health News:Louisiana State University Health Sciences Center research shows fish oil component given up to 5 hours after stroke limits brain damage 3Health News:Research shows gene-based test can prioritize smokers for lung cancer CT screening 2Health News:Research shows gene-based test can prioritize smokers for lung cancer CT screening 3
Use to prevent arm or leg drops during surgical procedures. The dimensions are 10"W x 6"H. These come in pairs. Optional Gel pad available (BD2245)...
... Precision Dynamics Corporation offers a ... serving infants to adults. Armboard ... non-woven material assuring easy cleaning ... cross contamination. Choose from three ...
... to fit almost every operating table. 3/D ... the sit of fixation to the operating ... be titled to any position the surgeon ... adjustment of the 3/D Swinger permits rotation ...
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Medicine Products: